BIO’s Evergreening Project: CEO Greenwood Discusses Cost-Effectiveness And The “Inevitability” Of Follow-On Biologics

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".